Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can common painkillers ease Parkinson's nerve pain? new study investigates.

NCT ID NCT02601586

Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether two drugs, oxycodone (a strong painkiller) and levodopa (a Parkinson's medication), can reduce nerve pain caused by Parkinson's disease. 67 adults with Parkinson's and chronic nerve pain took one of the drugs or a placebo for 8 weeks, alongside their usual treatment. The goal was to see if either drug could lower average pain intensity better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

67 people

The number who actually took part.

Started

Sep 2016

Finished

Nov 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Parkinson's disease according to the UKPDSBB (United Kingdom Parkinson's Disease Society Brain Bank) criteria * Patients suffering from chronic pain (lasting for more than 3 months) * Patients suffering from central neuropathic pain caused by PD, * Patients with a PD-related central neuropathic pain intensity of at least 3 points on the VAS (average intensity over the last month), * Patients with both types of pain (neuropathic and nociceptive) will be included if the neuropathic pain predominates * Patients treated with a stable regimen of dopaminergic drugs (levodopa and/or dopamine agonists) for at least 4 weeks before the study dan throughout the study * Patients with a stable step 1 analgesic (NSAIDS, acetaminophen) or coanalgesic (antidepressants, antiepileptic) treatment for at least 4 weeks before the study and throughout the study Exclusion Criteria: * Patients suffering from another parkinsonian syndrome * De Novo patients (patients never before treated with dopaminergic drugs) * Patients with intercurrent acute pain * Patients suffering from a chronic disease causing pain (rheumatoid arthritis, ankylosing spondylitis, diabetic neuropathy, cancer etc.) * Patients treated with neuroleptics * Patients with clinically detectable behavioural disorders and addiction * Patients with disabling dyskinesias * Patients with painful restless legs syndrome * Patients with cognitive impairment (MMS \< 25) or unable to complete the various scales used in the study * Hypersensitivity to oxycodone, levodopa, benserazide or a combination of these drugs * Patients treated with opioid drugs (step 2 and 3) * Patients treated with non-selective monoamine oxidase inhibitors (MAOI) * Patients with severe hepatocellular insufficiency * Patients with uncontrolled cardiovascular and pulmonary diseases * Persistent constipation that has already resulted in a subocclusive state * Patients treated with antiemetic neuroleptics * Patients with angle-closure glaucoma Exclusion criteria relating to MRI: * Patients with claustrophobia * Patients with a hearing aid, cardiac prosthesis, pacemaker, surgical clip * Patients refusing to be informed of abnormalities are detected on MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France

  • Chu Toulouse

    Toulouse, 31059, France

  • Henri Mondor Hospital

    Créteil, 94010, France

  • Hospital Pierre Wertheimer

    Lyon, France

  • Hospital of Aix-en-Provence

    Aix-en-Provence, 13616, France

  • Pitié-Salpêtrière Hospital

    Paris, 75651, France

  • University Hospital of Bordeaux

    Bordeaux, 33076, France

  • University Hospital of Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • University Hospital of Lille

    Lille, 59037, France

  • University Hospital of Limoges

    Limoges, 87042, France

  • University Hospital of Marseille

    Marseille, 13385, France

  • University Hospital of Nancy

    Nancy, France

  • University Hospital of Nantes

    Nantes, France

  • University Hospital of Nîmes - Caremeau

    Nîmes, France

  • University Hospital of Poitiers

    Poitiers, 86021, France

  • University Hospital of Rennes

    Rennes, 35033, France

  • University Hospital of Rouen

    Rouen, 76031, France

  • University Hospital of Strasbourg

    Strasbourg, 67098, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.